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We describe a 30-year-old woman with an infantile-onset epilepsy due to a left temporal gliotic area who developed a noncon-
vulsive status epilepticus (NCSE) during tiagabine (TGB) adjunctive therapy. The ictal EEG recording showed a de novo right
temporal focus not previously evident. After the i.v. administration of 4 mg lorazepam, the NCSE episode rapidly resolved and
her usual left temporal EEG abnormalities reappeared. To our knowledge this is the first case of paradoxical seizure exacerbation
associated with TGB therapy in which the clinical and EEG features are congruous with a new contralateral focus.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Paradoxical seizure exacerbation including status
epilepticus (SE) has been reported for several
antiepileptic drugs (AEDs)1. Tiagabine (TGB) is
a γ-aminobutyric acid (GABA) reuptake inhibitor
recently approved as adjunctive therapy for partial
seizures with or without secondary generalisation.
Nonconvulsive status epilepticus (NCSE) has been
reported in patients taking TGB2–11, but a recent
review of safety data opined that TGB adjunctive
therapy does not increase the risk of SE and NCSE12.
We report a case of NCSE in a TGB-treated patient
with an intractable epilepsy due to a perinatal gliotic
area at the left temporo-parietal level. Notably, the
clinical and EEG findings were indicative of a new
focus in the contralateral homotopic region.
CASE REPORT
A 30-year-old mildly retarded woman with a right
hemiparesis due to a perinatal left temporo-parietal
gliotic area was referred to our Epilepsy Service in
December 2000 because of a drug-resistant partial
epilepsy. The patient suffered from frequent complex
partial seizures (CPS) with rare secondary generalisa-
tion since late infancy. Many AEDs—carbamazepine,
phenytoin, phenobarbital, sodium valproate, benzo-
diazepines, vigabatrin, lamotrigine, topiramate—had
been employed with no satisfactory effect. Her CPS
started with a stereotyped change of facial expression
followed by staring and unresponsiveness. Thereafter,
a tonic deviation of gaze and headturning toward the
right occurred. Seizures lasted about 3 minutes with
a subsequent confusional state of 10–20 minutes. No
SE and NCSE episodes had ever been reported. Inter-
ictal EEGs were congruous with a left temporal focus
(Fig. 1).
On presentation to our centre, the patient—weighing
about 50 kg—was on topiramate 400 mg day−1,
carbamazepine 1200 mg day−1 and phenobarbital
100 mg day−1 but reported almost daily clusters of
CPS with rare generalisations. TGB was gradually in-
troduced with weekly increments of 5 mg day−1. One
week after TGB reached 45 mg day−1, the patient
appeared intermittently confused and was referred
to our emergency department. On examination she
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Fig. 1: EEG prior TGB therapy: short bursts of irregular spike-wave discharges at left temporal level.
Fig. 2: EEG during TGB-associated NCSE episode: diffuse slowing of background rhythm and frequent spike-wave discharges
on right temporal derivations spreading to contralateral regions.
NCSE due to a new focus during TGB therapy 321
Fig. 3: EEG after 4 mg lorazepam i.v.: clear improvement of background activity with appearance of left temporal spike-wave
discharges associated to rare contralateral sharp waves.
stared, reacted slowly and answered simple questions
in a delayed fashion. Moreover, a de novo negative
myoclonus involving the left arm was evident. Ictal
EEG showed a diffuse slowing of background rhythm
with frequent spike-wave discharges over right tem-
poral derivations spreading to the contralateral re-
gions (Fig. 2). After the i.v. administration of 4 mg
lorazepam, the patient’s mental status rapidly re-
turned to normal and the left arm negative myoclonus
ceased. EEG background improved and her usual
left temporal focus reappeared in association with
rare contralateral sharp waves (Fig. 3). A diagnosis
of complex partial NCSE was made and TGB was
stopped. No other seizures occurred during her stay on
our ward and 1 week later the patient was discharged.
The family refused any other change of therapy.
At the last follow-up visit in December 2001, her
seizure frequency was unchanged but no new NCSE
episode was reported.
DISCUSSION
Seizure exacerbation and induction of SE and NCSE
have been reported for several AEDs1. TGB is a
GABA reuptake inhibitor recently approved for the
add-on therapy of intractable partial epilepsies. Com-
mon side effects (headache, somnolence, dizziness,
generalised asthenia) are mild and usually related
to rapid dose titration. Prolonged states of impaired
consciousness have been described during TGB ad-
junctive therapy2–11, but a recent review of safety
data opined that TGB does not increase the risk of
SE and NCSE12.
We report a patient with a long-standing epilepsy
who developed an NCSE after TGB introduction.
Different from other reported cases2, 3, 5, 8, 9, 11, the
diagnosis of NCSE in our patient was suggested not
only by the ictal clinical and EEG findings but also
by the prompt response to lorazepam. A link between
TGB and NCSE in our patient can be assumed. In-
deed, no new event, other than TGB introduction,
was reported in the 3 months before that episode. SE
and NCSE never occurred in her previous history.
The progressive alteration in mental status appeared
soon after the TGB dose reached 45 mg day−1 (about
0.9 mg kg−1 day−1), similar to other patients receiving
TGB with enzyme-inducing AEDs2–6, 8, 10. Finally,
no other NCSE episode was reported after TGB was
stopped and the previous therapy was reintroduced.
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The paradoxical exacerbation of seizure activity in-
cluding NCSE by TGB has been related to its uns-
elective action on GABA-A and GABA-B receptors.
GABA-B-specific agonists may determine a primary
generalised NCSE in animals and humans13, but the
role of GABA-B receptors in the pathogenesis of com-
plex partial NCSE (as in our patient) remains unclear.
Interestingly, our patient developed an NCSE
episode due to a contralateral focus not previously
evident. She complained of frequent stereotyped CPS
and rare generalisations since late infancy. No pre-
vious ictal EEG was available but all her interictal
recordings were indicative of a left temporal focus
(Fig. 1), congruous with the perinatal temporo-parietal
gliotic area. The NCSE episode during TGB treat-
ment was completely different from her usual seizures
and the ictal EEG showed a new contralateral fo-
cus (Fig. 2). AED induction of seizures related to
a new contralateral focus has been reported in a
CBZ-treated infant with tonic–clonic seizures and
left interictal EEG abnormalities but never in adult
cases14. The right-sided focus in our patient could
already exist in the context of a multifocal epilepsy
with extremely rare or absent clinical manifestations.
The increase of GABA synaptic levels related to
TGB therapy may have triggered that focus into an
NCSE episode. A fascinating interpretation is that
TGB adjunctive therapy may have unmasked a hy-
pothetical ‘mirror focus’ related to the long-standing
left-sided focus. The ‘mirror focus’ concept derives
from the observation that an independent epileptic
focus can develop in the contralateral homotopic area
to which the primary focus sends direct synaptic pro-
jections and its formation is related directly to the
duration of illness and inversely to the age of seizure
onset15.
The features of the NCSE and the BDZ ef-
fect in our patient suggest a proconvulsant action
for TGB-mediated transmission through GABA-B
sites. To our knowledge this is the first report of a
TGB-associated NCSE whose ictal clinical and EEG
findings are congruous with a de novo contralateral
epileptic focus.
REFERENCES
1. Perucca, E., Gram, L., Avanzini, G. and Dulac, O. Antiepilep-
tic drugs as a cause of worsening seizures. Epilepsia 1998;
39: 5–17.
2. Schapel, G. and Chadwick, D. Tiagabine and non-convulsive
status epilepticus. Seizure 1996; 5: 153–156.
3. Eckardt, K. M. and Steinhoff, B. J. Nonconvulsive sta-
tus epilepticus in two patients receiving tiagabine treatment.
Epilepsia 1998; 39: 671–674.
4. Trinka, E., Moroder, T., Nagler, M., Staffen, W., Loscher,
W. and Ladurner, G. Clinical and EEG findings in complex
partial status epilepticus with tiagabine. Seizure 1999; 8: 41–
44, doi 10.1053/seiz.1998.0223.
5. Ettinger, A. B., Bernal, O. G., Andriola, M. R. et al. Two
cases of non-convulsive status epilepticus in association with
tiagabine therapy. Epilepsia 1999; 40: 1159–1162.
6. Holtkamp, M., Pfeiffer, M., Buchheim, K. and Meierkord, H.
Tiagabine and non-convulsive status epilepticus. Nervenarzt
1999; 70: 1104–1106.
7. Knake, S., Hamer, H. M., Schomburg, U. and Oertel, W.
H. Tiagabine-induced absence status in idiopathic general-
ized epilepsy. Seizure 1999; 8: 314–317, doi 10.1053/seiz.
1999.0303.
8. Balslev, T., Uldall, P. and Buchholt, J. Provocation of
non-convulsive status epilepticus by tiagabine in three ado-
lescent patients. European Journal of Paediatric Neurology
2000; 4: 169–170, doi 10.1053/ejpn.2000.0293.
9. Piccinelli, P., Borgatti, R., Perucca, E., Tofani, A., Donati,
G. and Balottin, U. Frontal nonconvulsive status epilepticus
associated with high-dose tiagabine therapy in a child with
familial bilateral perisylvian polymicrogyria. Epilepsia 2000;
41: 1485–1488.
10. Skodda, S., Kramer, I., Spittler, J. F. and Gehlen, W.
Non-convulsive status epilepticus in two patients receiving
tiagabine add-on treatment. Journal of Neurology 2001; 248:
109–112.
11. Fitzek, S., Hegemann, S., Sauner, D., Bonsch, D. and Fitzek,
C. Drug-induced nonconvulsive status epilepticus with low
dose of tiagabine. Epileptic Disorders 2001; 3: 147–150.
12. Shinnar, S., Berg, A. T., Treiman, D. M. et al. Status epilep-
ticus and tiagabine therapy: review of safety data and epi-
demiologic comparisons. Epilepsia 2001; 42: 372–379.
13. Solomon, G. E. and Labar, D. Hypothesis that tiagabine-
induced NCSE is associated with GABAergic hyperfunction,
with GABA(B) receptors playing a critical role, is supported
by a case of generalized NCSE induced by baclofen. Epilepsia
1998; 39: 1383.
14. Dhuna, A., Pascual-Leone, A. and Talwar, D. Exacerbation
of partial seizures and onset of nonepileptic myoclonus with
carbamazepine. Epilepsia 1991; 32: 275–278.
15. Morrell, F. and deToledo-Morrell, L. From mirror focus to
secondary epileptogenesis in man: an historical review. Ad-
vances in Neurology 1999; 81: 11–23.
